NCT06213259View on ClinicalTrials.gov

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

PHASE1RecruitingINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

January 6, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2025

Conditions

Rheumatoid Arthritis

Interventions

DRUG

KD6005

Biological: KD6005, SQ

DRUG

Placebo

Placebo, SQ

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shanghai Kanda Biotechnology Co., Ltd.

INDUSTRY